|
Monday, 20 October 2008 00:00 |
Inveni Capital invests in Medeia Therapeutics
Helsinki, Finland and Munich, Germany - October 20, 2008 - Inveni Capital announced today an investment in Medeia Therapeutics Ltd., a Finnish drug discovery company focused on neurodegenerative diseases. Inveni Capital was the lead investor in the financing round. Seed Fund Vera Ltd., an existing investor in the company, also participated in the financing round.
Medeia Therapeutics Ltd., founded in 2006, is a drug discovery company focused on novel therapeutics for neurodegenerative diseases such as stroke, Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Medeia’s discovery platforms are centered on the expertise of Medeia’s scientific founders in the field of molecular medicine and include programs based on both small molecule and cell therapy approaches. Medeia has partnered its lead small molecule program with Orion Corporation.
The funds raised in the financing round will be used for the expansion of Medeia’s small molecule and cell therapy product programs and for advancing the new product candidates within these programs through preclinical proof-of-concept.
Inveni Capital is a Finnish-German life science venture fund. Inveni extends hands-on entrepreneurial experience to guide early-stage companies to commercial success.
For further information contact:
Medeia Therapeutics
Milla Koistinaho, CEO
Microkatu 1
70210 Kuopio, Finland
Tel: +358 44 590 0603
E-mail: milla.koistinaho@
medeiatherapeutics.com
www.medeiatherapeutics.com
|
Inveni Capital
Markku Jalkanen
Viikinkaari 6
00790 Helsinki, Finland
Tel: +358 40 520 6124
E-mail:
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
www.invenicapital.com
|
| |
|
| |
|
|